AbbVie has completed its acquisition of Aliada Therapeutics and is now a part of AbbVie.

Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system (CNS).

"Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age," said Dawn Carlson, MD, MPH, Vice President, Neuroscience Development at AbbVie.

"With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform," Carlson added.

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. The company strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.